key: cord-0899369-9ljbueyh authors: Silecchia, Gianfranco; Boru, Cristian E.; Maria Marinari, Giuseppe; Gentileschi, Paolo; Morino, Mario; Olmi, Stefano; Foletto, Mirto; Bernante, Paolo; Morganti, Riccardo; Tascini, Carlo; Anselmino, Marco title: Laparoscopic bariatric surgery is safe during phase 2-3 of covid-19 pandemic in italy: a multicenter, prospective, observational study date: 2021-06-13 journal: Diabetes Res Clin Pract DOI: 10.1016/j.diabres.2021.108919 sha: 2e2fcddcbfa3ee5e6ceb836e23b977e7374bc38c doc_id: 899369 cord_uid: 9ljbueyh BACKGROUND: Sars-Cov-2 epidemic in Italy caused one of the greatest 2020 European outbreaks, with suspension of elective bariatric/metabolic surgery (BMS). From May 2020 a significant decline of the epidemic has been observed (phase 2); National Health Service protocols permitted elective BMS’ resumption. A new, more severe COVID-19 surge, the “second wave”, started on October 2020 (phase 3). AIM: the primary end point was to analyze the outcomes of any Sars-Cov-2 infection and related morbidity/mortality within 30 POD after laparoscopic BMS during phase 2-3; secondary end points were readmission and reoperation rates. METHODS: Study design prospective, multicenter, observational. Setting Eight Italian high-volume bariatric centers. All patients undergoing BMS from July 2020 through January 2021 were enrolled according to the following criteria: no Sars-Cov-2 infection; primary procedures; no concomitant procedure; age >18<60 years; compensated comorbidities; informed consent including COVID-19 addendum; adherence to specific admission, in-hospital and follow-up protocols. Data were collected in a prospective database. Patients undergone BMS during July-December 2019 were considered a control group. RESULTS: 1258 patients were enrolled and compared with 1451 operated on in 2019, with no differences for demographics, complications, readmission, and reintervention rates. Eight patients (0·6%) and 15 healthcare professionals tested positive for Sars-Cov-2 infection, with no related complications or mortality. CONCLUSIONS: Introduction of strict COVID-19 protocols concerning the protection of patients and health-care professionals guaranteed a safe resumption of elective BMS in Italy. The safety profile was, also, maintained during the second wave of outbreak, thus allowing access to a cure for the obese population. A temporary suspension of the bariatric surgical programs all over the world was one of the immediate consequences of the Sars-Cov-2 virus generated pandemics, especially in Italy, the first European country seriously affected by the Coronavirus disease 2019 (COVID-19). The first indigenous person-to-person Sars-Cov-2 transmission in Italy was reported on February 2 nd , and by March 3 rd , 2020 all elective bariatric and metabolic surgical procedures (BMS) were suspended. Due to the rapid spread and the aggressive nature of the virus it was considered safer to postpone all elective surgical procedures, in order to preserve the resources and significantly curb the viral transmission/circulation. 1 BMS is a highly demanding resource field, both human and logistics, involving activities at high risk of transmission, such as airway management. 2 One year later more than 3,101,000 coronavirus cases, and over 100,000 related deaths, have been registered in Italy (http://www.salute.gov.it/portale/home.html). Obesity represents a chronic disease, a pro-coagulant and pro-inflammatory state which may increase the risk of thrombosis and exaggerated cytokines and oxidative stress response. 3 The role of obesity during the outbreak has not been ignored, being independently associated with increased risk for intensive care unit (ICU) admission and intubation. 4 Obesity, an already recognized pandemic itself, being associated with a higher risk of infectious diseases, in particular of the respiratory tract, 5, 6 plays an important role in a more serious outcomes from Sars-Cov-2 infection, with a higher risk of developing severe pneumonia, especially in men. 7, 8 Furthermore, obesity is associated with, and responsible for, comorbid conditions that may represent an increased risk of unfavorable Sars-Cov-2 infection outcomes. 9, 10 So far, BMS represents the most effective treatment in obtaining a long-term meaningful weight loss, 11 and resolution of related comorbidities, including respiratory disorders. [12] [13] [14] Recent findings suggests that BMS is associated with a lower rate of mortality and hospital admission in patients with obesity who, afterwards become infected with SARS-CoV-2. 2, 15 In May 2020, a slight decrease of the pandemic was observed in Italy and a gradual and progressive decrease of the lockdown restrictions was started (phase 2), when the virus was supposed to be under control and protocols and regulations were guiding National Healthcare System (SSN) in order to restart elective surgical practice, including BMS. In a previous paper we reported the results of a multicenter retrospective study, evaluating the risk of infection during 840 BMS procedures, performed without specific precautions during January-February 2020 (when the circulation of the virus has been demonstrated). 16 We found five infections (5.9 cases of 1000 inhabitants), two had mild symptoms requiring home treatment, and three were hospitalized for fever and dyspnea; none died, all made a full recovery. In the same group of patients, the rate of postoperative complications was similar in comparison to the rate recorded in patients undergoing BMS in the eight centers during the same period of 2019: 14 severe complications (Clavien-Dindo III-IV grade classification) 17 This was a multicenter, prospective, observational study carried out in eight Italian, SSN's high-volume bariatric centers ( The protocol respects the STROBE statement and checklist, 18 and did not change during the study's period: July 2020 -January 2021. Candidates were enrolled according to the following criteria: no previous Sars-Cov-2 infection; primary bariatric surgery; no concomitant procedure, excluding hiatal hernia repair; no previous major abdominal surgery; >18<60 years old; compensated comorbidities; BMI < 60 kg/m 2 ); laparoscopic standard bariatric procedure endorsed by Italian Society for Obesity Surgery (SICOB); estimated procedure duration < 120 minutes; official SICOB's surgical informed consent given, including COVID-19 and participation to the study addendums. All the participating centers followed the standard recruitment, ambulatory (including telemedicine) and in-hospital, OR and after discharge protocols, updated to the national and regional guidelines (supplementary material). 19,20,21 Patients with obesity were considered eligible for surgery, maximizing equity of access and minimizing the harm from delayed access. 22, 23 Hospital admission, in-hospital and OR management and after discharge protocols Hospital admission protocol included: the patient being checked 2-3 days before admission by telephone interview (table 2), to rule out fever (threshold value > 37.5ºC / 99.5ºF), respiratory symptoms, vomiting, diarrhea, conjunctivitis, changes in smell or taste, osteoarticular pain, excessive fatigue, or contact in the previous two weeks with a confirmed case (clinical diagnosis -positive swab for Sars-Cov-2); a PCR / antigenic swab Sars-Cov-2 test was performed in all enrolled patients 24-48 hours prior to hospital admission. The medical staff repeated the above interview on admission and the patient received and signed a specific COVID-19 consent, together with specific bariatric operation consent and participation in the study. Further screening before admission consisted of a chest X-ray or CT-scan, and blood analysis. Operating Room (OR) protocol: standard personal protective equipment (PPE) plus N95 masks for the surgeons, while for the anesthesiologists and nurses who managed the airways and gastric bougie positioning, the N99 mask was recommended, using face shields, single-use waterproof gowns, and double gloves; restricted access in the OR; expert surgeons and anesthesiologists performed the procedures to minimize the OR occupation time; a smoke evacuator system was employed to avoid air-borne contamination; in the alternative, a filter was connected to the exsufflation system. A negative pressure in the OR was not mandatory, but it was crucial to allow enough time between consecutive cases for a change of air in the room. When the OR was used for intensive care during phase 1 of the pandemic, proper sanitization was a necessity. no COVID-19 hospital/section was used for elective BMS; standard PPE for staff was mandatory; social distancing had to be respected even in the case of post-surgical mobilization; patients had to wear a surgical mask at all times. Each patient received a single room, however in the case of a larger ward being used, he/she was assigned a suitable space in compliance with social distancing regulations. ERAS protocol was used whenever possible. Where more than 48 hours hospitalization was needed, Sars-Cov-2 tests were performed on discharge. No visitors were allowed. All caregivers were required to wear masks at all times. Policies were implemented to transfer COVID-19 patients to other facilities. After discharge: In the case of intra-hospital contact with Sars-Cov-2 positive patient or healthcare professional, 14 days self-quarantine after discharge was mandatory. After 7 and 15 p.o. days patients received a follow-up phone call, with specific questions about COVID-19 (table 2) to quantify the number of symptomatic patients, who were tested, and diagnosed with COVID-19. First outpatient visit was scheduled for the 30 th p.o. day., when the same data acquiring protocol was used. Patients were not involved in designing the research questions, outcome measures, or interpretation or writing up of results of this study. Patients' representatives, in our ethics committee, were asked for comments on general comprehensibility. The patients' representatives of each participating hospital were informed about the study and its start. Results will be presented to patients and public as part of regular information events. Information on patient demographics including age, sex, Body Mass Index (BMI) and comorbidities, operation details such as the type and duration of BMS, were collected. Perioperative outcomes including length of stay, ICU admissions, Emergency Department (ED) visits, re-admissions, re-operation, complications, and mortality within 30 days were also analyzed. For the 2020 cohort, pre-and post-operative Sars-Cov-2 PCR testing results and the development of any related symptoms were included. The Rt index, or the R number, describes the average number of secondary infections generated by an infected person on a certain date. It was used by the Italian Government to monitor the progression of the epidemic. A value of Rt above the threshold (Rt 1), even in presence of a low number of cases, was interpreted as an alarming sign of the escalating trend of the epidemic. All data were collected from a prospectively maintained, online registry. In this prospective observational longitudinal study, categorical data were described by absolute and relative frequency, continuous data by mean, standard deviation and range. To compare qualitative and quantitative clinical/anthropometric factors between the two groups of study (2019; 2020-21) z-test for two proportions and t-test (two-tailed) were used, respectively. Significance was fixed at 0·05 and all analyses were carried out by SPSS v.27 software. Role of the funding source: the funder of the study had no role or support in the study design, data collection, data analysis, data interpretation, or writing of the report. Elective laparoscopic BMS in the eight participating centers, was made up on a cohort of 1258 patients, vs. 1451 patients operated during June -December 2019, with no difference in demographics, complications, readmission, and reintervention rates (table 3) . Follow-up was completed in 100% of the cases for each center. No conversion to open surgery was encountered, with only one perioperative death registered, due to pulmonary thromboembolism (0·07%) in the study group. Sleeve gastrectomy (LSG) was the most common procedure (88·2%); more LSGs were performed in 2020, while more R-en-Y gastric bypasses were performed in 2019, when statistically compared. All related comorbidities were registered, hypertension, obstructive sleep apnea and diabetes being most frequent, and were more associated in the control group, without showing any significant difference (table 4) . Eight patients (0·6%), 6 females / 2 males, with a mean BMI 44·1 kg/m 2  4·9, a mean age 37 years  6·2, tested positive for Sars-Cov-2, predominantly undergoing LSG. Diagnosis was established after hospital discharge (asymptomatic patients, Sars-Cov-2 swab negative tests), from which only one required admission to the Infective Disease Unit. No complications, no pneumonia, no admission to the ICU, nor mortality relating to Sars-Cov-2 were registered. At This is the first multicenter, prospective, observational study on the safety and feasibility of BMS during the COVID-19 Italian epidemic, performed during two distinct periods: the socalled phase 2, low incidence phase (June-September 2020), and phase 3 or second wave (October 2020 -January 2021), the latter still ongoing as we proffer this manuscript. As a matter of fact, during the second Italian wave 1,822,841 positive cases were registered vs. 236,134 registered during the first wave of the pandemic. Among over 100,000 Italian victims of COVID-19, obesity was identified as a risk factor in 10·8%, for both genders. 26 Nevertheless, resuming elective BMS was mandatory given the uncertainty regarding the effects and duration of the outbreak, combined with the progressive nature of obesity and related conditions, while delaying BMS could have increased the risk of morbidity and mortality in surgical candidates. 23 The risk of harm during the surgical process, however, is different for each patient, depending on the type and severity of disease and their suitability for BMS. Patients undergoing BMS are not at increased risk of Sars-Cov-2 infection compared to the general population. The 30-day morbidity and mortality following BMS performed during the phase 2-3, with appropriate perioperative protocols, appeared to be similar to the prepandemic levels, as shown in a recent retrospective, observational, international cohort study on 2116 adult patients who underwent primary BMS in 133 hospitals from 35 countries. 27 There were ten (0·5%) symptomatic cases diagnosed after BMS, similar to the one reported in our study, both before and during the pandemic. Patients who had BMS would have a decrease in their fat stores, improvement of their comorbidities, and hence make them less susceptible to severe outcomes if they catch Sars-Cov-2 infection. 28 A nationwide French study was conducted on 8286 individuals with a previous diagnosis of obesity, admitted for COVID-19 between January 1 st and May 15 th , 2020; 541 patients had a history of BMS 15 . The need for invasive mechanical ventilation and death occurred in 7% and 3.5% of the BMS group versus 15% and 14.2% of the control group, respectively, so BMS is independently associated with a reduced risk of death and invasive mechanical ventilation. The restart of elective BMS, performed under strict, updated in-hospital and ambulatory regulations, based on national and international guidelines 19-23,29 was analyzed for the first 30 POD Sars-Cov-2 incidence, its mortality, and complications, as well as the perioperative readmission or reoperation rate. Only 8 patients (0·6%) tested positive for Sars-Cov-2 postoperatively, and diagnosis was established after hospital discharge. The 0·6% rate Sars-Cov-2 infection at 30 days seems to be related to the family / environment link, without excluding the possibility that infections occurred during the hospitalization, and patients became positive or symptomatic after discharge, at home. Five of these patients were located in North Italy, the area most affected during this pandemic, while the rest are located in Rome metropolitan area, highly affected, as well, during the second wave. No specific conditions were registered for these 8 patients, nor for their morbid obesity or associated conditions. No concomitant patients and health professionals were recorded or could be demonstrated. The 15 healthcare professionals infected were involved in a greater variety of in-hospital and ambulatory activities, not restricted to the bariatric area, and we could not find a direct connection between them and the patients who tested positive after hospital discharge. We consider that infections among patients or personnel were completely unrelated. There was no difference for bariatric surgery's complications, perioperative readmission or reoperation rate between the 2 analyzed periods, except for anastomotic bleedings and postoperative pulmonary embolism (only one event registered in 2020). The lower number of procedures performed in 2020 in the eight centers (13·5% reduction compared to 2019, without reaching a significant cutoff) is easy to comprehend: all the involved centers faced serious difficulties in this period, determined by the reduction in available ORs, allocated hospital admissions, more complicated in-hospital patients management. Additionally, all centers faced temporary closure (for 2-3 weeks or even more) during the second wave of the pandemic (October 20 -January 21). Nevertheless, the cohorts were similar, with no difference in characteristics. This is the first multicenter prospective observational study, on a large scale, demonstrating the safety of elective BMS in selected patients when strict protective protocols are adopted. The results of the present study, first to our knowledge in Europe, demonstrate that the bariatric surgical program can guarantee a safe standard of care for selected bariatric patients, thus, avoiding the postponement of surgical treatment. On the basis of the current epidemiological data in Italy we consider that maintaining strict protective protocols, the vaccination of the professional and the priority of vaccination of the obese patients as fragile subpopulation can guarantee a safe standard of care, thereby, avoiding a further BMS suspension. Continuing to deliver surgical treatment to the obese population represents a preventive and protective strategy in the long term. The selection of the patients in our study excluded super-super-obese and estimated time-consuming procedures to minimize the need for postoperative ICU. At least in our country a balance between hospital resources and severely obese patients was needed, allowing a safe delivery of surgical care even during the second wave. The results of the present study allow patients, on waiting list, to be informed about the risk of Sars-Cov-2 infection after surgery and add data to the informed consent. A significant cooperation between hospital governance and professionals, helped in achieving these results. Respect of the protocols, the monitoring of the local epidemiological events, and the resilience of the multidisciplinary team are our key points. The selection criteria of the patients, the strict, protective protocols adopted by the participating hospitals allowed the prevention of in-hospital Sars-Cov-2 infection and guaranteed a safe resumption of bariatric surgery, with a view to continuing the fight against obesity during the outbreak. Considering the pandemic situation and Italian epidemiology, the present data support the weight loss surgery program, not only, in Italy but worldwide. The vaccination of health professionals, telemedicine, in-hospital protective and preventive tools, enhance the safe profile of bariatric surgery, considering that obesity, per se, represents a negative prognostic factor in case of Sars-Cov-2 infection. all the data in the study and accept responsibility to submit for publication. We declare no competing interests. The metadata will be available through the dedicated online platform https://test-3mstudy.pantheonsite.io/user/login and will be available for secondary analysis once the study has completed. Table 2 . Patients' COVID-19 questionnaire over the phone: preoperative (2 days before hospital admission) and postoperative (7 th & 14 th postoperative day and directly at the outpatient visit on the 30 th ). Preoperative (2 days before admission, over the phone) During the 30 days prior to the surgery did you travel abroad or outside your region or were you exposed to people that travelled abroad / outside your region? During the 30 days prior to the surgery were you exposed to people who were diagnosed with COVID-19? Yes/ no. How, how long? During the 30 days prior to the surgery did you experience any symptoms concerning of Sars-Cov-2 positive Non tested 8 (0·6) 0·01 Leak (sleeve) 8 (0·6) 5 (0·4) 0·646 Bleeding 22(1·7) 11 (1) 0·163 Anastomotic bleeding 2 (0·14) 1 (0·07) <0·001 Wound infection 6 (0·4) 6 (0·4) 0·760 Deep vein thrombosis 1 (0·07) 1 (0·07) 0·817 Pulmonary embolism 0 (0) 1 (0·07) 0·004 Abscess 1 (0·07) 2 (0·1) 0·692 Occlusion 1 (0·07) 2 (0·1) 0·692 Others 10 (1·1) 6 (0·5) 0·130 Collaborators. The Impact of the COVID-19 Pandemic on Bariatric Surgery: Results from a Worldwide Survey Managing COVID-19 in Surgical Systems Association of Bariatric Surgery with Clinical Outcomes of SARS Infection: a Systematic Review and Meta-analysis in the Initial Phase of COVID-19 Association of obesity with illness severity in hospitalized patients with COVID-19: A retrospective cohort study Obesity and risk of subsequent hospitalization with pneumonia Obesity and risk of infection: results from the Danish Blood Donor Study Risk of COVID-19 for patients with obesity Clinical characteristics of 145 patients with corona virus disease 2019 (COVID-19 Case-Fatality Rate and Characteristics of Patients Dying in Relation to COVID-19 in Italy Endocrine and metabolic link to coronavirus infection Meta-analysis: surgical treatment of obesity Metabolic surgery versus conventional medical therapy in patients with type 2 diabetes: 10-year follow-up of an open-label, singlecenter, randomized controlled trial Weight Regain and Diabetes Evolution After Sleeve Gastrectomy: a Cohort Study with over 5 Years of Follow-Up Review of the key results from the Swedish Obese Subjects (SOS) trial -a prospective controlled intervention study of bariatric surgery The Impact of Previous History of Bariatric Surgery on Outcome of COVID-19. A Nationwide Medico-Administrative French Study Bariatric and metabolic surgery during COVID-19 outbreak phase 2 in Italy: why, when and how to restart Classification of surgical complications: a new proposal with evaluation in a cohort of 6336 patients and results of a survey The Strengthening the Reporting of Observational Studies in Epidemiology (STROBE) statement: guidelines for reporting observational studies Società italiana di Chirurgia Oncologica, Società Italiana di Chirurgia Cardiaca e Le attivita chirurgiche in era Covid: riflessioni e proposte organizzative per un correto approcio alla fase 2 della pandemia. A cura del tavolo tecnico sulla chirurgia Surgery in COVID-19 patients: operational directives Raccomandazioni per la sicurezza dei pazienti durante l'emergenza Coronavirus-Italian Network for Safety in Health Care Bariatric surgery and the COVID-19 pandemic: SICOB recommendations on how to perform surgery during the outbreak and when to resume the activities in phase 2 of lockdown Bariatric and metabolic surgery during and after the COVID-19 pandemic: DSS recommendations for management of surgical candidates and postoperative patients and prioritisation of access to surgery 21 26 Members of the SARS-CoV-2 Surveillance Group. Characteristics of SARS-CoV-2 patients dying in Italy Mahawar K for the GENEVA collaborators. Global 30-day outcomes after bariatric surgery during the COVID-19 pandemic (GENEVA): an international cohort study Bariatric and Metabolic Surgery Can Prevent People with Obesity from COVID-19 Infection EAES Group of Experts for Recovery Amid COVID-19 Pandemic. EAES Recommendations for Recovery Plan in Minimally Invasive Surgery Amid COVID-19 Pandemic The study was partially funded, unconditionally, by a research grant from Johnson & Johnson, that was used exclusively for database creation and maintenance, data collecting. This funding source had no role or support in the study design, data collection, data analysis, data interpretation, or writing of the report.We would like to thank all the staff supporting study delivery at participating sites and all participants for their ongoing commitment and contributions to this study. We also thank Alexandru Berendei, Bucharest, IT specialist, developer & manager of the dedicated online platform and to Dr. Alberto Di Biasio, data manager.